Shots:

• The P-III EMPEROR-Preserved trial evaluates the safety & efficacy of empagliflozin (10mg- qd) vs PBO in 5988 patients with chronic HFpEF
• The results demonstrated a 21% reduction in risk for composite 1EPs of CV death or hospitalization for HF. The 2EPs showed a 27% reduction in risk of first & recurrent hospitalizations for HF & slowed kidney function decline- safety data were consistent with previous findings with well-established safety profile of empagliflozin- results are published in the NEJM
• The companies plan for regulatory submissions globally in 2021. If approved- empagliflozin will be the 1st therapy across the HF spectrum

  Ref: Businesswire | Image: Boehringer Ingelheim